VEGFA and age-related macular degeneration: Furthermore, gene therapy (RGX-314, gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein, phase 2 clinical trial, https://clinicaltrials.gov/ct2/show/NCT04832724?cond=RGX-314&draw=2&rank=2) may entirely revolutionize PCV and AMD treatment.